Emma Court Robert Langreth

Drugmakers have been rushing to develop obesity pills (to rival obesity shots like Wegovy), angling for a piece of a market that some estimate will one day be worth as much as $100 billion.

Market Insights

COVID continues to put a damper on health, pharma industries

October 30, 2020

For drugmakers, the pandemic has squeezed demand for everything from childhood vaccines to smoking-cessation drugs.

Trending Stories

1
Enterprise ICHRA: A Playbook for Benefits Advisors
2
Mark Cuban praises Trump's PBM executive order, predicts 'hundreds of billions' in savings
3
Arkansas law bans PBM ownership of pharmacies
4
Whole Foods settles its 401(k) excessive fee lawsuit that cost workers millions
5
401(k) contribution limit projections for 2026: Milliman

For questions about BenefitsPRO, please call 800-458-1734 (9:00am-5:30pm ET, Monday through Friday, except holidays), or send an email to [email protected].

TopicsBenefits Broker Benefits Manager Retirement Advisor Expert Perspectives Special Reports Luminaries Advisor of the Year

ResourcesWebcasts Podcasts Resource Center Events Career Center Judy Diamond Sitemap

SupportAbout Us Advertise With Us Asset & Logo Licensing Contact Us

LegalCookie Policy Terms of Service Privacy Policy

Your Account Sign In Create Account Forgot Password My Newsletters

Business & Finance Network of Sites

ThinkAdvisor PropertyCasualty360 BenefitsPRO Credit Union Times GlobeSt Treasury & Risk Consulting Mag Bookstore